Immune cell therapy takes on untreatable liver cancer

NCT ID NCT07713290

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study tests an experimental treatment called GKL-006, made from a person's own immune cells (iNKT cells), for liver cancer that cannot be surgically removed. Participants receive GKL-006 injections along with a standard procedure that blocks the tumor's blood supply (TACE). The main goal is to check safety and tolerability, with early looks at whether the cancer shrinks or progression slows.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental iNKT cell therapy called GKL-006, given by injection, combined with a standard liver cancer procedure called transarterial chemoembolization (TACE)
What this could lead to
If this works, it could offer a new treatment option for people with liver cancer that cannot be removed by surgery.
What could go wrong
This is a very early, small study (6 people) focused mainly on safety. The treatment may not shrink tumors or improve survival, and cell therapies can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Ditan Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100015, China

  • Beijing You An Hospital

    Beijing, Beijing Municipality, 100069, China

  • First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, 030001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.